EU research projects

IDF Europe welcomes the opportunity to take an active role in EU-funded research and other initiatives that aim at improving the health of European citizens, as these contribute to finding new treatments for diabetes and improving the lives of people living with this condition.

Developed within the EU Seventh Framework Programme (FP7) and Horizon 2020 research and innovation programme, these projects encourage the development and validation of new therapies, methods for health promotion and prevention, as well as sustainable and efficient healthcare systems. IDF Europe is currently involved in the following projects: The Open projectCarpeDiab and Feel4diabetes. Past projects in which IDF Europe involved in were EConda, EUROCONDOR, Manage Care, JA-CHRODIS, EuRhythdia and ePredice

  • The OPEN project- Outcomes of Patients’ Evidence with Novel, Do-it-Yourself Artificial Pancreas Technology

    OPEN project logoIDF Europe is part of the OPEN project consortium, which establish an evidence-base surrounding the impact of Do-it-Yourself Artificial Pancreas Systems (DIY APS) on people with diabetes and wider healthcare systems. IDF Europe role is to facilitate the knowledge exchange by, among others hosting some scientific researchers and helping to disseminate the findings of the research..

    The OPEN project, launched in 2018, aims to examine clinical outcomes of those using DIY AP systems by analysing changes in quality and experiences of the users that will ultimately enable technological and predictive capacity improvements of the system.

    The novel feature of this project is the extent of public and patient involvement

    Contact our project officer Winne Ko to learn more on IDF Europe involvement in the project

    For more information, visit the OPEN project website: 



  • CarpeDiab - Integrated e-health solution for self-management of type 2

    CarpediabCarpeDiab aims to be an advanced service for type 2 diabetes management. The project, which has received funding from the European Union's Horizon 2020, expects to have an impact on the behaviour of patients and the healthcare professionals to take full advantage of the possibility that technology opens.

    IDF Europe is part of the consortium that brings expertise from 6 European countries: Italy, The Netherlands, Turkey, Spain, Belgium and Germany, which leads it.

    CarpeDiab will continue its activity in 2019.  For more information, please visit:


    Evidence has accumulated that disruption of our body’s internal clock (the so-called circadian clock) might contribute to the development of Type 2 diabetes and other cardiometabolic complications.

    Few studies have investigated the link between the disruption of the daily sleep-wake pattern and Type 2 diabetes in man. For this reason, a multi-disciplinary consortium of leading academic experts and research-intensive SME’s have joined forces under EuRhythDia, the Consortium on chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population. This 5-year project will look at whether lifestyle change to reset the internal clock can significantly reduce the risk of developing Type 2 diabetes and cardiometabolic complications. 

    Principal investigator: Prof Rainer Böger

    Past event(s):

    24 May 2017- Workshop at the German Diabetes Congress, Hamburg, Germany 

    June 2017 - International Taskforce for Prevention of Cardiometabolic Diseases, Aachen, Germany 

    Poster (English)

    Press Release (English)

    Press Release (French)

    Press Release (German)

    Press Release (Italian)

    Press Release (Polish)

    Press Release (Spanish)


© 2019 International Diabetes Federation Disclaimer